BACKGROUND: Epigenetic therapy has had a significant impact on the management of hematologic malignancies, but its role in the treatment of ovarian cancer remains to be defined. The authors previously demonstrated that treatment of ovarian and breast cancer cells with DNA methyltransferase and histone deacetylase (HDAC) inhibitors can up-regulate the expression of imprinted tumor suppressors. In this study, demethylating agents and HDAC inhibitors were tested for their ability to induce re-expression of tumor suppressor genes, inhibiting growth of ovarian cancer cells in culture and in xenografts. METHODS: Ovarian cancer cells (Hey and SKOv3) were treated with demethylating agents (5-aza-20-deoxycytidine [DAC] or 5-azacitidine [AZA]) or with HDAC inhibitors (suberoylanilide hydroxamicacid [SAHA] or trichostatin A [TSA]) to determine their impact on cellular proliferation, cell cycle regulation, apoptosis, autophagy, and re-expression of 2 growth inhibitory imprinted tumor suppressor genes: guanosine triphosphate-binding Di-RAS-like 3 (ARHI) and paternally expressed 3 (PEG3). The in vivo activities of DAC and SAHA were assessed in a Hey xenograft model. RESULTS: The combination of DAC and SAHA produced synergistic inhibition of Hey and SKOv3 cell growth by apoptosis and cell cycle arrest. DAC induced autophagy in Hey cells that was enhanced by SAHA. Treatment with both agents induced re-expression of ARHI and PEG3 in cultured cells and in xenografts, correlating with growth inhibition. Knockdown of ARHI decreased DAC-induced autophagy. DAC and SAHA inhibited the growth of Hey xenografts and induced autophagy in vivo. CONCLUSIONS: A combination of DAC and SAHA inhibited ovarian cancer growth while inducing apoptosis, G2/M arrest, autophagy, and re-expression of imprinted tumor suppressor genes. Cancer
BACKGROUND: Epigenetic therapy has had a significant impact on the management of hematologic malignancies, but its role in the treatment of ovarian cancer remains to be defined. The authors previously demonstrated that treatment of ovarian and breast cancer cells with DNA methyltransferase and histone deacetylase (HDAC) inhibitors can up-regulate the expression of imprinted tumor suppressors. In this study, demethylating agents and HDAC inhibitors were tested for their ability to induce re-expression of tumor suppressor genes, inhibiting growth of ovarian cancer cells in culture and in xenografts. METHODS:Ovarian cancer cells (Hey and SKOv3) were treated with demethylating agents (5-aza-20-deoxycytidine [DAC] or 5-azacitidine [AZA]) or with HDAC inhibitors (suberoylanilide hydroxamicacid [SAHA] or trichostatin A [TSA]) to determine their impact on cellular proliferation, cell cycle regulation, apoptosis, autophagy, and re-expression of 2 growth inhibitory imprinted tumor suppressor genes: guanosine triphosphate-binding Di-RAS-like 3 (ARHI) and paternally expressed 3 (PEG3). The in vivo activities of DAC and SAHA were assessed in a Hey xenograft model. RESULTS: The combination of DAC and SAHA produced synergistic inhibition of Hey and SKOv3 cell growth by apoptosis and cell cycle arrest. DAC induced autophagy in Hey cells that was enhanced by SAHA. Treatment with both agents induced re-expression of ARHI and PEG3 in cultured cells and in xenografts, correlating with growth inhibition. Knockdown of ARHI decreased DAC-induced autophagy. DAC and SAHA inhibited the growth of Hey xenografts and induced autophagy in vivo. CONCLUSIONS: A combination of DAC and SAHA inhibited ovarian cancer growth while inducing apoptosis, G2/M arrest, autophagy, and re-expression of imprinted tumor suppressor genes. Cancer
Authors: Violetta V Leshchenko; Pei-Yu Kuo; Rita Shaknovich; David T Yang; Tobias Gellen; Adam Petrich; Yiting Yu; Yvonne Remache; Marc A Weniger; Sarwish Rafiq; K Stephen Suh; Andre Goy; Wyndham Wilson; Amit Verma; Ira Braunschweig; Natarajan Muthusamy; Brad S Kahl; John C Byrd; Adrian Wiestner; Ari Melnick; Samir Parekh Journal: Blood Date: 2010-04-28 Impact factor: 22.113
Authors: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Charles S Dietrich; Victoria L Greenberg; Christopher P DeSimone; Susan C Modesitt; John R van Nagell; Rolf Craven; Stephen G Zimmer Journal: Gynecol Oncol Date: 2009-10-28 Impact factor: 5.482
Authors: Min Xie; Yongli Kong; Wei Tan; Herman May; Pavan K Battiprolu; Zully Pedrozo; Zhao V Wang; Cyndi Morales; Xiang Luo; Geoffrey Cho; Nan Jiang; Michael E Jessen; John J Warner; Sergio Lavandero; Thomas G Gillette; Aslan T Turer; Joseph A Hill Journal: Circulation Date: 2014-01-06 Impact factor: 29.690
Authors: Weiqun Mao; Haley L Peters; Margie N Sutton; Aaron F Orozco; Lan Pang; Hailing Yang; Zhen Lu; Robert C Bast Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Zachary Benson; Saeed H Manjili; Mehran Habibi; Georgi Guruli; Amir A Toor; Kyle K Payne; Masoud H Manjili Journal: Biochem Pharmacol Date: 2017-08-10 Impact factor: 5.858
Authors: Clinton R Bartholomew; Tsukasa Suzuki; Zhou Du; Steven K Backues; Meiyan Jin; Melinda A Lynch-Day; Midori Umekawa; Avani Kamath; Mantong Zhao; Zhiping Xie; Ken Inoki; Daniel J Klionsky Journal: Proc Natl Acad Sci U S A Date: 2012-06-25 Impact factor: 11.205
Authors: Paul G Thomes; Rebecca A Ehlers; Casey S Trambly; Dahn L Clemens; Howard S Fox; Dean J Tuma; Terrence M Donohue Journal: Autophagy Date: 2012-10-22 Impact factor: 16.016
Authors: Alexandra Giatromanolaki; Efthimios Sivridis; Achileas Mitrakas; Dimitra Kalamida; Christos E Zois; Syed Haider; Charitomeni Piperidou; Aglaia Pappa; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis Journal: Cancer Biol Ther Date: 2014 Impact factor: 4.742